The guideline offers clear, concise, and actionable recommendation statements to help clinicians to incorporate recommendations into clinical practice, with the goal of improving quality of care. Each recommendation is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms.

The Maudsley® Prescribing Guidelines in Psychiatry The new edition of the world-renowned reference guide on the use of medications for patients presenting with mental health problems The Maudsley Prescribing Guidelines in Psychiatry is the essential evidence-based handbook on the safe and effective prescribing of psychotropic agents. Covering both common and complex prescribing situations encountered in day-to-day clinical practice, this comprehensive resource provides expert guidance on drug choice, minimum and maximum doses, adverse effects, switching medications, prescribing for special patient groups, and more. Each clear and concise chapter includes an up-to-date reference list providing easy access to the evidence on which the guidance is based. The fourteenth edition has been fully updated to incorporate the latest available research, the most recent psychotropic drug introductions, and all psychotropic drugs currently used in the UK, USA, Canada, Australia, New Zealand, and Japan. Several new sections cover topics such as deprescribing of major psychiatric drugs, prescribing psychotropics at the end of life, the treatment of agitated delirium, the genetics of clozapine prescribing, the use of weekly penfluridol, and the treatment of psychotropic withdrawal. Featuring contributions by an experienced team of psychiatrists and specialist pharmacists, the new edition of The Maudsley Prescribing Guidelines in Psychiatry: Provides succinct coverage of drug treatment of psychiatric conditions and formulating prescribing policy in mental health Covers a wide range of psychiatric conditions including schizophrenia, bipolar disorder, depression and anxiety, borderline personality, eating disorders, and many others Provides advice on prescribing for children and adolescents, older people, pregnant women, and other special patient groups Offers new sections on genetic prescribing, long-acting injectable formulations, ketamine administration and uses, and dopamine super-sensitivity Includes referenced information on off-label prescribing, potential interactions with other substances such as alcohol, tobacco, and caffeine, and treating patients with comorbid physical conditions Whether in the doctor’s office, in the clinic, or on the ward, The Maudsley Prescribing Guidelines in Psychiatry, Fourteenth Edition is a must-have for psychiatrists, pharmacists, neuropharmacologists, clinical psychologists, nurses, and other healthcare professionals working in mental health, as well as trainees and students in medicine, pharmacy, and nursing.

Over the next 30 years, the number of chronically mentally ill people 55 years of age and older will double. With multiple disorders relating to mental illness and old age, this population will require unique services from a health care system that is ill prepared to deliver them. This is the first major multidisciplinary reference on this important topic. Coverage includes information on demographic and clinical characteristics of older schizophrenic persons, treatment approaches, research strategies, and economic and health policy issues.

These guidelines from NICE set out clear recommendations, based on the best available evidence, for health care professionals on how to work with and implement physical, psychological and service-level interventions for people with various mental health conditions.The book contains the full guidelines that cannot be obtained in print anywhere else. It brings together all of the evidence that led to the recommendations made, detailed explanations of the methodology behind their preparation, plus an overview of the condition covering detection, diagnosis and assessment, and the full range of treatment and care approaches. There is a worse prognosis for psychosis and schizophrenia when onset is in childhood or adolescence, and this new NICE guideline puts much-needed emphasis on early recognition and assessment of possible psychotic symptoms. For the one-third of children and young people who go on to experience severe impairment as a result of psychosis or schizophrenia the guideline also offers comprehensive advice from assessment and treatment of the first episode through to promoting recovery.This guideline reviews the evidence for recognition and management of psychosis and schizophrenia in children and young people across the care pathway, encompassing access to and delivery of services, experience of care, recognition and management of at-risk mental states, psychological and pharmacological interventions, and improving cognition and enhancing engagement with education and employment.

"In Mental Health: From Policy to Practice, the editors and contributors use their extensive experience and knowledge of mental health services to analyse the effectiveness of developments. They reflect on how policy has developed, what policy means for practice, to what extent policy has been implemented, and where the challenges lie." --Book Jacket.

A concise review of current research into suicide providing a guide to understanding this disease and its increasing incidence globally.